Drugs / QIV-HD
QIV-HD
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03233217 | Sep → Nov 2017 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT04537234 | Nov 2020 → Feb 2021 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT04498832 | Oct 2020 → Jan 2021 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT03282240 | Sep → Nov 2017 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05624606 Comparator | Nov 2022 → Mar 2024 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QIV-HD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05624606 ↗ |
| Known as | High-Dose Quadrivalent Influenza Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04498832 ↗ |
| Known as | IIV4-HD | “quadrivalent high-dose split-virion inactivated influenza vaccine (IIV4-HD)” PMID 31431411 ↗ Aug 2019 |
| Modality | Vaccine | “high-dose Quadrivalent influenza vaccine (QIV-HD)” NCT03233217 ↗ |
| Route | Intramuscular | “QIV-HD by IM route” NCT03233217 ↗ |